# Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects

> **NCT01244880** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 4 (actual)

## Conditions studied

- Healthy

## Interventions

- **OTHER:** Saline
- **DRUG:** PF-02545920
- **OTHER:** Ketamine
- **DRUG:** PF-02545920
- **OTHER:** Saline
- **OTHER:** Placebo
- **OTHER:** Ketamine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01244880
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2014-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01244880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01244880, "Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01244880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*